Opinion
Video
Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
Author(s):
“The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.”
In this video, Francesca Jackson-Spence,MBChB, BMedSc, MRCP, highlights the ongoing phase 3 SAMETA trial (NCT05043090) in MET-driven locally advanced or metastatic papillary renal cell carcinoma. The trial was initiated based on findings from the study, “Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO; NCT02819596),” which was presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California.
Jackson-Spence is a clinical research fellow in genitourinary oncology at Barts Cancer Institute, Queen Mary’s University in London.
Video Transcript:
SAMETA is an open-label randomized phase 3 study. It has 3 arms. It's comparing the savolitinib and durvalumab combination, durvalumab monotherapy, and sunitinib monotherapy. It's completed its enrollment; we've recruited around 200 patients globally. The study is conducted in that MET-driven subset, so patients with advanced papillary renal cancer that have MET-driven tumors. The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.
This transcript was AI generated and edited by human editors for clarity.
